Pharmanutra SpA is an Italy-based company engaged in the healthcare industry. The Company develops nutraceutical products and medical devices. It focuses on studying and producing formulations that are backed up in scientific research. It is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The Company offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.

Employees

111

Sector

Pharmaceuticals

Calendar

2024-11-10 - Q3 2024 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
24-09-17	58.80 €	+0.34%	1,318
24-09-16	58.60 €	-2.66%	6,116
24-09-13	60.20 €	+1.01%	5,093
24-09-12	59.60 €	0.00%	5,561
24-09-11	59.60 €	0.00%	15,660

Real-time Borsa Italiana, September 17, 2024 at 03:29 am

More quotes

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

58.60EUR

Average target price

81.33EUR

Spread / Average Target

+38.79%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Real-time Borsa Italiana Other stock markets 03:29:45 2024-09-17 EDT			5-day change	1st Jan Change
58.80 ^EUR	+0.34%		+9.50%	+4.26%

09-12	Lists expected to rise on ECB day	AN
09-11	Mib down slightly, traders waiting for ECB	AN

Capitalization	563M 626M 851M	P/E ratio 2024 *	32.7x	P/E ratio 2025 *	27.2x
Enterprise value	545M 606M 823M	EV / Sales 2024 *	4.88x	EV / Sales 2025 *	4.19x
Free-Float	34.32%	Yield 2024 *	1.51%	Yield 2025 *	1.72%

Lists expected to rise on ECB day	09-12	AN
Mib down slightly, traders waiting for ECB	09-11	AN
Brent resumes USD70 and pushes Saipem higher	09-11	AN
Indices up; Saipem recovers opens on top	09-11	AN
Mib up; focus on U.S. CPI	09-11	AN
Mib down, Saipem down with Brent below USD70	09-10	AN
Piazza Affari in the red; Amplifon sinks the Mib.	09-10	AN
Business Square up; UK unemployment falls	09-10	AN
PharmaNutra's indicators grow in the first half of the year	09-09	AN
The market burns its idols	09-09
Indices up; UniCredit tops the Mib	09-09	AN
Pharmanutra S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2024	09-08	CI
Stock exchanges veer downward; MPS closes Mib list	09-03	AN

PHARMANUTRA S.P.A.: THE DISTRIBUTION OF IRON-BASED DIETARY SUPPLEMENTS KICKS OFF IN MEXICO	06-27	AQ
Pharmanutra S p A : 13/06/2024 - A NEW STUDY HIGHLIGHTS THE EFFICACY, SUPERIORITY AND IMPROVED TOLERABILITY OF SIDERAL® COMPARED TO CONVENTIONAL IRON SUPPLEMENT TREATMENTS	06-13	PU
The importance of iron in pregnancy: benefits for mothers and babies	05-02	PU
Pharmanutra S p A : Merger by incorporation of Junia Pharma S.r.l. and Alesco S.r.l. into PharmaNutra S.p.A.	05-02	PU
Pharmanutra S p A : ANNUAL FINANCIAL REPORT OF 31 DECEMBER 2023	03-25	PU

Pharmanutra S.p.A. Stock

Equities

PHN

IT0005274094

Pharmaceuticals

Valuation: Pharmanutra S.p.A.

Chart: Pharmanutra S.p.A.

Latest news: Pharmanutra S.p.A.

Press Releases: Pharmanutra S.p.A.

News in other languages: Pharmanutra S.p.A.

Trading Pharmanutra S.p.A.

Quotes and Performance

Course Extremes

Managers and Directors: Pharmanutra S.p.A.

ETFs: Pharmanutra S.p.A.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

Pharmanutra S p A : RELAZIONE FINANZIARIA SEMESTRALE SULLA GESTIONE 30/06/2024	09-13
Listini attesi in rialzo nel giorno della BCE	09-12
Mib di poco giù, trader in attesa della BCE	09-11
Brent riprende quota USD70 e spinge Saipem	09-11
Indici in rialzo; Saipem recupera apre in vetta	09-11

1 day	+0.34%
1 week	+9.50%
Current month	+8.69%
1 month	+19.51%
3 months	+27.14%
6 months	-0.34%
Current year	+4.26%

Director	Title	Age	Since
Andrea Lacorte CEO	Chief Executive Officer	-	02-12-31
Germano Tarantino CTO	Chief Tech/Sci/R&D Officer	-	-
Carlo Volpi COO	Chief Operating Officer	-	08-12-31

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
PHARMANUTRA S.P.A.	+0.34%	+9.50%	+9.50%	-11.71%	627M
ELI LILLY AND COMPANY	-0.02%	+1.68%	+60.43%	+299.73%	832B
NOVO NORDISK A/S	-0.95%	+3.43%	+41.05%	+184.16%	609B
JOHNSON & JOHNSON	+0.89%	+0.23%	+3.43%	+1.07%	402B
ABBVIE INC.	+0.78%	-0.35%	+28.67%	+81.10%	346B
MERCK & CO., INC.	+1.81%	+2.21%	+9.71%	+63.90%	299B
ROCHE HOLDING AG	+0.61%	-1.12%	+3.08%	-22.46%	251B
ASTRAZENECA PLC	+0.77%	-2.74%	+12.47%	+49.65%	246B
NOVARTIS AG	+0.56%	+0.16%	+7.55%	+27.80%	236B
AMGEN INC.	+0.85%	+2.87%	+28.59%	+54.24%	180B
Average	+0.24%	+1.38%	+20.45%	+72.75%	340.16B
Weighted average by Cap.	+0.02%	+1.15%	+29.47%	+126.98%

	2024 *	2025 *
Net sales	114M 127M 172M	130M 145M 197M
Net income	17.33M 19.27M 26.18M	20.87M 23.2M 31.52M
Net Debt	-5.8M -6.45M -8.76M	-16.4M -18.23M -24.77M